检验医学与临床Issue(24)：3443-3444,2.DOI:10.3969/j.issn.1672-9455.2014.24.023
恩替卡韦联合保肝药物治疗肝硬化失代偿期患者的疗效分析
Therapeutic effects of entecavir combined with hepatoprotective therapy in patients with end-stage cirrhosis
杨静 1伍锡刚 1张杰2
作者信息
- 1. 四川省雅安市人民医院 感染科
- 2. 四川省雅安市人民医院 消化内科 625000
- 折叠
摘要
Abstract
Objective To observe the therapeutic effects of oral application of entecavir combined with hepato‐protective drugs in patients with end‐stage cirrhosis after hepatitis B .Methods A total of 120 patients with end‐stage cirrhosis after hepatitis B ,treated in this hospital during Jan .2009 and Jan .2012 ,were randomly divided into two groups .The control group (n=60) was treated with hepatoprotective drugs ,while the treatment group (n=60) was treated with entecavir (0 .5 mg/d) combined with hepatoprotective drugs .After 96 weeks of treatment ,levels of liver function ,C3 ,C4 ,hepatitis B virus (HBV)‐DNA and the adverse reactions were compared between the two groups . Results After 96 weeks of treatment ,the serum levels of alanine aminotransferase (ALT ) ,aspartate aminotrans‐ferase (AST ) and total bilirubin (TB) of the two groups decreased significantly ,and the levels of treatment group were significantly lower than control group (P<0 .05) .Complement C3 and C4 levels in the two groups were signifi‐cantly increased after treatment ,and the levels of treatment group were significantly higher than control group (P<0 .05) .After treatment ,the survival rate of treatment group was 79 .0% ,higher than the 43 .0% of control group (P<0 .05) .There was no statistically significant differences of the incidence of adverse reactions between the two groups (P<0 .05) .Conclusion Hepatoprotective therapy combined with entecavir could reduce liver damage ,protect liver immune function and improve survival rate of patients with end‐stage cirrhosis after hepatitis B ,without increas‐ing of adverse reaction incidence .关键词
恩替卡韦/乙型肝炎/终末期/免疫Key words
entecavir/hepatitis B/end-stage/immune引用本文复制引用
杨静,伍锡刚,张杰..恩替卡韦联合保肝药物治疗肝硬化失代偿期患者的疗效分析[J].检验医学与临床,2014,(24):3443-3444,2.
